The predictive factors of prognosis and treatment strategies for small-cell carcinoma (SCC) of the urinary tract are controversial.
This study was aimed to investigate the clinical experience and management of patients with SCC of the urinary tract. We collected data of patients who were diagnosed with genitourinary SCC (GSCC) between 2002 and 2013 and were treated in the Fudan University Shanghai Cancer Center. A total of 18 patients were diagnosed with GSCC of which 10 originated from the prostate, seven from the bladder and one from the adrenal gland. The mean follow-up time was 15.5 months and progression-free survival (PFS) was 9.3 months. Primary tumor resection was attempted in 13 of 18 patients (72.2%) in whom radical surgery was performed in six of 14 (42.9%) limited disease patients. Most of the patients (13, 72.2%) received cisplatin-based chemotherapy. Patients who had normal lactic dehydrogenase (LDH) levels showed a significantly higher median PFS and overall survival (OS) compared with patients with high LDH levels (P = 0.030, P= 0.010). Patients with limited disease treated with a radical operation experienced a non-significant (P = 0.211) longer PFS compared with patients who were not treated, but this reached statistical significance after analyzing OS (P = 0.211, P= 0.039). Our patients showed a poor prognosis as reported previously. Serum LDH levels beyond the normal range indicate a poor prognosis. For GSCC patients who are diagnosed with limited disease, radical surgery is strongly recommended along with cisplatin-based chemotherapy.
Written by:
Chang K, Dai B, Kong YY, Qu YY, Gan HL, Gu WJ, Ye DW1, Zhang HL, Zhu Y, Shi GH. Are you the author?
Department of Urology and Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Reference: Asian J Androl. 2014 Mar 28. Epub ahead of print.
doi: 10.4103/1008-682X.127811
PubMed Abstract
PMID: 24713837
UroToday.com Prostate Cancer Section
